Literature DB >> 35249190

Pre-exposure to Aerosolized Polyvalent Bacterial Lysates Protects Against Bleomycin-Induced Pulmonary Fibrosis in Mice.

Xiaoling Zhu1, Shan Yuan1, Xiaofang Zheng1, Xiaorong Wang2, Jinnong Zhang3.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial pneumonia of unknown cause. No therapeutic modalities can reverse or stop its ever-deteriorating course. The stimulation of lung innate immunity using bacterial lysates was found to protect against lethal pulmonary infection. Hence, this study aimed to explore whether the immune-stimulating enhancement by pretreatment with bacterial lysates led to protection against bleomycin-induced pulmonary fibrosis. C57BL/6 mice were randomly divided into 4 groups with 20 mice in each group. The mice were exposed to an aerosolized mixture of polyvalent bacterial lysates (PVBL) or phosphate-buffered saline (PBS) three times on separate days. Twenty-four hours after the last exposure, the lungs were intratracheally infused with bleomycin (BLM) or normal saline (NS). The pulmonary morphology, Ashcroft's scale of pulmonary fibrosis, and levels of pro-inflammatory cytokines such as interferon (IFN)-γ and interleukin (IL)-4 were evaluated 14 days after the intratracheal infusion. The exposure to PVBL did not induce any discernible structural abnormalities in the lungs, while the IFN-γ/IL-4 ratio increased. BLM-induced pulmonary fibrosis was associated with an overwhelming downregulation of IFN-γ and IL-4 expression. Pre-exposure to PVBL protected against BLM-induced pulmonary fibrosis, which was demonstrated by a greater reduction of Ashcroft's fibrotic score and a greater decrease in the hydroxyproline level in the lungs. Although the PVBL pre-exposure did not restore the BLM-induced downregulation of IL-4 and IFN-γ levels, the IFN-γ/IL-4 ratio was still maintained greater than the animals with BLM infusion. BLM-induced murine pulmonary fibrosis is associated with downregulation of IFN-γ and IL-4 levels. Pre-exposure to the aerosolized PVBL protects against BLM-induced pulmonary fibrosis.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  bleomycin-induced pulmonary fibrosis; immunomodulation.; polyvalent bacterial lysates

Mesh:

Substances:

Year:  2022        PMID: 35249190     DOI: 10.1007/s10753-022-01653-w

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  28 in total

1.  Different profiles of notch signaling in cigarette smoke-induced pulmonary emphysema and bleomycin-induced pulmonary fibrosis.

Authors:  Shi Li; Xiaofei Hu; Zheng Wang; Meng Wu; Jinnong Zhang
Journal:  Inflamm Res       Date:  2015-03-27       Impact factor: 4.575

2.  Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival.

Authors:  K R Flaherty; G B Toews; J P Lynch; E A Kazerooni; B H Gross; R L Strawderman; K Hariharan; A Flint; F J Martinez
Journal:  Am J Med       Date:  2001-03       Impact factor: 4.965

3.  Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.

Authors:  Ganesh Raghu; Kevin J Anstrom; Talmadge E King; Joseph A Lasky; Fernando J Martinez
Journal:  N Engl J Med       Date:  2012-05-20       Impact factor: 91.245

4.  Innate immunity alterations in idiopathic interstitial pneumonias and rheumatoid arthritis-associated interstitial lung diseases.

Authors:  Ilias C Papanikolaou; Kyriaki A Boki; Evangelos J Giamarellos-Bourboulis; Antigoni Kotsaki; Konstantinos Kagouridis; Napoleon Karagiannidis; Vlasis S Polychronopoulos
Journal:  Immunol Lett       Date:  2014-12-23       Impact factor: 3.685

Review 5.  Corticosteroids in idiopathic pulmonary fibrosis.

Authors:  J P Lynch; E White; K Flaherty
Journal:  Curr Opin Pulm Med       Date:  2001-09       Impact factor: 3.155

Review 6.  Treatment strategies for idiopathic interstitial pneumonias.

Authors:  Athol U Wells; Maria Kokosi; Konstantinos Karagiannis
Journal:  Curr Opin Pulm Med       Date:  2014-09       Impact factor: 3.155

7.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

8.  Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.

Authors:  Fernando J Martinez; Joao A de Andrade; Kevin J Anstrom; Talmadge E King; Ganesh Raghu
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

9.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Roland M du Bois; Ganesh Raghu; Arata Azuma; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Kevin R Flaherty; David M Hansell; Yoshikazu Inoue; Dong Soon Kim; Martin Kolb; Andrew G Nicholson; Paul W Noble; Moisés Selman; Hiroyuki Taniguchi; Michèle Brun; Florence Le Maulf; Mannaïg Girard; Susanne Stowasser; Rozsa Schlenker-Herceg; Bernd Disse; Harold R Collard
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

10.  Mortality Trends in Rheumatoid Arthritis: Zooming in on Interstitial Lung Disease.

Authors:  Pankti Reid; Sabina A Guler
Journal:  Ann Am Thorac Soc       Date:  2021-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.